Prevention of postmenopausal osteoporosis: how effective is transdermal hormone substitution?
Author(s): Gass R, Neff M Affiliation(s): Institut fur Sozial- und Praventivmedizin, Universitat Zurich. Publication date & source: 1995-08-26, Schweiz Med Wochenschr., 125(34):1583-91. Publication type: Clinical Trial; Randomized Controlled Trial QUESTION: Can osteoporosis and cardiovascular risk be effectively and simultaneously prevented with transdermal estradiol replacement therapy (in combination with norethisterone acetate 1 mg per day, oral, cyclically for 12 days monthly)? METHODS: A selected, representative group of healthy women with an average age of 52 years, with confirmed natural menopause for 1 to 4 years, randomly allocated to a treatment-group with hormone replacement (n = 42) and a control-group (n = 70), with homogeneous main parameters in the two groups, can be compared, without distortion of the findings, during the period of the two-year intervention study: the purely trabecular bone mass in the distal radius was specifically measured, prospectively, with the hig